Adaptimmune enters $125M financing deal after Genentech terminates potential $3B partnership
Adaptimmune Therapeutics entered into a $125 million debt financing deal Wednesday with Hercules Capital. Under their terms of the five-year loan deal, Adaptimmune (NASDAQ: ADAP) received an initial $25 million upon close of the financing. The cell therapy …